Contrast-enhanced MR imaging of hand and finger joints in patients with early rheumatoid arthritis: do we really need a full dose of gadobenate dimeglumine for assessing synovial enhancement at 3 T?

Purpose: To investigate the diagnostic value of a half dose compared with a full dose of gadobenate dimeglumine in the assessment of synovitis or tenosynovitis in the wrist and finger joints in patients with early rheumatoid arthritis (RA) and a disease activity score greater than 3.2.

Materials And Methods: With institutional review board approval and informed consent, 57 patients with early RA underwent 3-T magnetic resonance (MR) imaging with two different doses of contrast media.

Comparison of Gd-DTPA and Gd-BOPTA for studying renal perfusion and filtration.

Purpose: To measure the systematic error in perfusion and filtration parameters derived from magnetic resonance (MR) renography caused by protein binding of MR contrast agents.

Materials And Methods: Eight healthy Danish Landrace pigs were examined with dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). In four pigs a bolus of gadopentetate-dimeglumine (Gd-DTPA; no protein binding) was injected, followed by gadobenate-dimeglumine (Gd-BOPTA; 10% protein binding).

Gd-BOPTA for assessment of myocardial viability on MRI: changes of T1 value and their impact on delayed enhancement.

Gadobenate (Gd-BOPTA), injected at a dose of 0.1 mmol/kg body weight, was compared with gadopentetate (Gd-DTPA), injected at a dose of 0.2 mmol/kg body weight, for delineation of myocardial infarction interindividually in two groups of 26 patients each.

Three-dimensional contrast-enhanced magnetic-resonance angiography of the renal arteries: interindividual comparison of 0.2 mmol/kg gadobutrol at 1.5 T and 0.1 mmol/kg gadobenate dimeglumine at 3.0 T.

The purpose was to evaluate the image quality of high-spatial resolution MRA of the renal arteries at 1.5 T after contrast-agent injection of 0.2 mmol/kg body weight (BW) in an interindividual comparison to 3.

Temporal constraints in renal perfusion imaging with a 2-compartment model.

Objective: To assess the required temporal resolution and total acquisition time for renal perfusion and filtration measurements with a 2-compartment model.

Material And Methods: Saturation-recovery TurboFLASH perfusion measurements of 15 healthy volunteers were acquired at 1.5 T, with a temporal resolution of 1 second during the first pass and a total acquisition time of 270 seconds.

Intraindividual comparison of high-spatial-resolution abdominal MR angiography at 1.5 T and 3.0 T: initial experience.

Purpose: To prospectively compare three-dimensional (3D) contrast material-enhanced abdominal magnetic resonance (MR) angiography at 1.5 and 3.0 T intraindividually in healthy volunteers.

Intraindividual comparison of MR-renal perfusion imaging at 1.5 T and 3.0 T.

Purpose: The purpose of this study was to intraindividually compare fast gradient-echo semiquantitative renal perfusion measurements at 1.5 Tesla (T) and 3.0 Tesla.

Semiquantitative assessment of first-pass renal perfusion at 1.5 T: comparison of 2D saturation recovery sequences with and without parallel imaging.

Objective: The purpose of this study was to assess the feasibility and reliability of measurements performed with true fast imaging with steady-state free precession (FISP) and turbo fast low-angle shot (FLASH) sequences with parallel imaging compared with those obtained with turbo FLASH sequences without parallel imaging in first-pass renal perfusion MRI.

Subjects And Methods: The subjects in this prospective study were 15 healthy men who volunteered to undergo MRI for acquisition of renal perfusion measurements. Imaging was performed at 1.

Renal perfusion: comparison of saturation-recovery TurboFLASH measurements at 1.5T with saturation-recovery TurboFLASH and time-resolved echo-shared angiographic technique (TREAT) at 3.0T.

Purpose: To investigate the dependence of semiquantitative renal perfusion parameters on the acquisition technique and field strength used.

Materials And Methods: After intravenous injection of 7-mL Gd-chelates, high-temporal-resolution turbo fast low-angle shot (TurboFLASH) renal perfusion measurements were performed on eight healthy volunteers at 1.5T and another eight healthy volunteers at 3.

Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T.

Rationale And Objective: The objective of this study was to compare 0.1 and 0.2 mmol/kg body weight (bw) doses gadobenate dimeglumine (Gd-BOPTA; MultiHance) and gadobutrol (Gd-BT-DO3A; Gadovist) for cerebral perfusion magnetic resonance (MR) imaging at 1.

Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla.

Objectives: We sought to determine the relaxivity and accurate relaxation rates of Gd-DTPA, Gd-BT-DO3A, and Gd-BOPTA at 0.2, 1.5, and 3 T in human blood plasma.

Regional lung perfusion: assessment with partially parallel three-dimensional MR imaging.

Purpose: To evaluate partially parallel three-dimensional (3D) magnetic resonance (MR) imaging for assessment of regional lung perfusion in healthy volunteers and patients suspected of having lung cancer or metastasis.

Materials And Methods: Seven healthy volunteers and 20 patients suspected of having lung cancer or metastasis were examined with 3D gradient-echo MR imaging with partially parallel image acquisitions (fast low-angle shot 3D imaging; repetition time msec/echo time msec, 1.9/0.

Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.

Purpose: To evaluate the safety of and compare the enhancement characteristics of gadobenate dimeglumine (MultiHance; Bracco Imaging, Milan, Italy) with those of a standard gadolinium chelate (gadopentetate dimeglumine, Magnevist; Schering, Berlin, Germany) in primary and secondary brain tumors on the basis of qualitative and quantitative parameters, on an intraindiviual basis.

Materials And Methods: Twenty-seven patients with either high-grade glioma or metastases were enrolled in a bicentric intraindividual crossover study to compare lesion enhancement with doses of 0.1 mmol per kilogram of body weight of 0.

Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison.

Rationale And Objectives: Gadobenate dimeglumine (Gd-BOPTA) has a two-fold higher T1 relaxivity compared with gadopentetate dimeglumine (Gd-DTPA) and can be used for both dynamic and delayed liver MRI. This intraindividual, crossover study was conducted to compare 0.05 mmol/kg Gd-BOPTA with 0.